Posts by: David Melamed, PhD

David Melamed, PhD

David earned a PhD in Biological Sciences from Columbia University in New York, NY, where he studied how Drosophila ovarian adult stem cells respond to cell signaling pathway manipulations. This work helped to redefine the organizational principles underlying adult stem cell growth models. He is currently a Science Writer, as part of the BioNews Services writing team.

November 19, 2020November 19, 2020

Puerto Rico to Test miR’s ‘Liquid Biopsy’ in Detecting Prostate Cancers

News

The Puerto Rico Health Insurance Administration (ASES) has signed an agreement with miR Scientific to evaluate the economic and health benefits of using the miR Sentinel PCC4 Assay, also called ... Read more

November 3, 2020November 3, 2020

CAR T-Cell Therapy, MB-105, Shows Promise in Metastatic CRPC Patient in Phase 1 Trial

News

A heavily pretreated patient with metastatic castration-resistant prostate cancer (mCRPC) showed significant benefits, including a 94% decrease in the levels of the prostate-specific antigen (PSA) biomarker, one month after receiving ... Read more

September 24, 2020September 24, 2020

Phase 1 Trial of Oral Treatment for Metastatic CRPC Doses First Patient

News

A first patient has been dosed in a Phase 1 clinical trial investigating the small molecule inhibitor EPI-7386 as a treatment for metastatic castration-resistant prostate cancer (CRPC), its developer, ESSA ... Read more

September 3, 2020September 3, 2020

‘Eat It to Beat It’ Challenge to Honor Prostate Cancer Awareness Month

News

To honor Prostate Cancer Awareness Month this September, the Prostate Cancer Foundation (PCF) has launched its “Eat It to Beat It” challenge with the endorsement of celebrity ambassador Harry ... Read more

February 12, 2020February 12, 2020

UPenn Researchers Awarded $500K Grant to Develop CAR T-cell Therapy for Advanced PC

News

A research team at the Abramson Cancer Center of the University of Pennsylvania has been awarded a $500,000 grant from the Alliance for Cancer Gene Therapy (ACGT) to develop ... Read more

January 20, 2020

Zuclomiphene Safely Eases Hot Flashes Linked to ADT Use, Phase 2 Trial Reports

News

Interim Phase 2 trial results show that Veru‘s experimental treatment zuclomiphene citrate is well-tolerated and significantly reduces hot flashes in advanced prostate cancer patients using androgen deprivation therapy (ADT). ... Read more